OUR STORY
Don After Clinical Trial
Page 10
|
We had optimistically hoped that Biogen's drug had turned back Don's clock. We met with his neurologist in June 2020, and by this time, he has missed six infusions. She has seen him regress 20-25%. He is losing his ability to regulate his body temperature and is thirsty again. His balance is starting to be a concern too.
I cannot let him die, knowing there is a drug that has worked for him. I don't understand why Biogen's drug worked for Don, but on a scientific level, I believe it warrants further exploration. He IS the volunteer that should be studied, the case subject that proves efficacy. We are pleading with them to revisit their policy and allow him access to their drug BIIB092, Gosuranemab. Please take the time to learn how you can help in the next page. |
